Relationship between clinical efficacy of electroconvulsive therapy with Matrix Metalloproteinase-9 and Stromal cell-derived factor-1a serum levels in patients with mania

Not Applicable

Completed

Conditions: bipolar disorder type one-manic episode.
bipolar affective disorder

Registration Number: IRCT201410221556N66

Lead Sponsor: Kurdistan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 30

Inclusion Criteria

1) diagnosis by Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (American Psychiatric Association, 2013), of a bipolar I disorder (manic episode) 2) age between 18 to 45 years old 3) The minimal score on Young Mani Rating Scale (YMRS)=20 4) Signed informed consent 5) IQ>70 6) ASA class 1 or 2
Exclusion criteria:
1) a history of ECT during the preceding 6-month period; (2) use of nonbenzodiazepine anticonvulsants (valproate, carbamazepine, lamotrigine, or topiramate), lidocaine, theophylline, or lithium during the last week; (3) a history of rapid-cycling or mixed bipolar illness, schizophrenia, or another psychotic disorder that was not part of the mood disorder; (4) neurological illness or severe medical illness, 5) pregnancy, 6) stroke within the past 3 months, 7) brain surgery 8) severe head trauma, 9) drug or alcohol dependence within the past 2 years.

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of mania. Timepoint: 24 hours before beginning ECT and 24 hours after first, third and sixth sessions of ECT. Method of measurement: by Young Mania Rating Scale (YMRS).;Serum level of MMP9. Timepoint: before anesthesia, 10 minutes, and 6 hours after first, thisrd and sixth sessions of ECT. Method of measurement: ELISA test.;Serum level of SDF1a. Timepoint: before anesthesia, 10 minutes, and 6 hours after first, thisrd and sixth sessions of ECT. Method of measurement: ELISA test.

Secondary Outcome Measures